[A20-41] Avelumab (renal cell carcinoma) - Addendum to Commission A19-95
Last updated 14.05.2020
Project no.:
A20-41
Commission:
Commission awarded on 06.04.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment-naive adults with advanced renal cell carcinoma
Result of dossier assessment:
Conclusion of dossier assessment A19-95 unchanged.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-95 | Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G17-09 | Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-05-14 A G-BA decision was published.